Analyst firms · Morgan Stanley · LEGN

Morgan Stanley LEGN price target and rating history

Legend Biotech Corporation (LEGN) · Health Care

Morgan Stanley rates Legend Biotech Corporation (LEGN) Overweight with a $55 price target, as of its latest action on Mar 7, 2022. It has published 4 rating actions on LEGN since October 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a LEGN price target in the last 12 months, the median target is $26.

Current rating
Overweight
Price target
$55
Median target, all firms
$26
Actions on LEGN
4

Morgan Stanley price target on LEGN

$55$53$5120222023202420252026
Morgan Stanley price target on LEGN, each point a stated target, October 2021 to March 2022.

Every Morgan Stanley rating on LEGN

How other firms rate LEGN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Evercore ISIIn-lineNov 13, 2026
OppenheimerPerform$75Aug 12, 2026
UBSNeutral$28Jul 24, 2026
Rothschild & Co RedburnNeutral$24Feb 12, 2026
TD CowenHold$21Jan 22, 2026

Questions about Morgan Stanley and LEGN

What is Morgan Stanley's price target for LEGN?
Morgan Stanley's latest stated price target for Legend Biotech Corporation (LEGN) is $55, from its action on Mar 7, 2022.
What is Morgan Stanley's rating on LEGN?
Morgan Stanley rates LEGN Overweight, a bullish rating, as of Mar 7, 2022.
When did Morgan Stanley last change its view on LEGN?
On Mar 7, 2022, Morgan Stanley raises its price target to $55 from $51, keeps Overweight.
How does Morgan Stanley's LEGN target compare with other analysts?
Across 4 firms with a LEGN price target in the last 12 months, the median target is $26.

All Morgan Stanley ratingsLEGN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.